PriceTargets.com logo

LianBio - LIAN Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $3.50
  • Forecasted Upside: 1,220.75%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.27 As of 12/20/2024 01:00 AM ET
▲ +0.0123 (4.87%)

This chart shows the closing price for LIAN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LianBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LIAN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LIAN

Analyst Price Target is $3.50
▲ +1,220.75% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for LianBio in the last 3 months. The average price target is $3.50, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 1,220.75% upside from the last price of $0.27.

This chart shows the closing price for LIAN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 2 polled investment analysts is to reduce stock in LianBio. This rating has held steady since October 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/3/2024Bank of AmericaDowngradeBuy ➝ Underperform$5.00 ➝ $3.00
12/22/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $4.00
10/25/2023Raymond JamesLower TargetOutperform ➝ Outperform$15.00 ➝ $9.00
10/14/2022Raymond JamesLower TargetOutperform$27.00 ➝ $15.00
11/26/2021Bank of AmericaInitiated CoverageBuy
11/26/2021The Goldman Sachs GroupInitiated CoverageNeutral$18.58
11/26/2021Jefferies Financial GroupInitiated CoverageBuy$24.00
11/24/2021Raymond JamesInitiated CoverageOutperform$27.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
LianBio logo
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $0.27
Low: $0.25
High: $0.27

50 Day Range

MA: $0.29
Low: $0.26
High: $0.32

52 Week Range

Now: $0.27
Low: $0.27
High: $4.99

Volume

14,151 shs

Average Volume

1,037,083 shs

Market Capitalization

$28.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of LianBio?

The following Wall Street analysts have issued stock ratings on LianBio in the last twelve months: Bank of America Co., and Jefferies Financial Group Inc..
View the latest analyst ratings for LIAN.

What is the current price target for LianBio?

0 Wall Street analysts have set twelve-month price targets for LianBio in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 1,220.8%. Jefferies Financial Group Inc. has the highest price target set, predicting LIAN will reach $4.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $3.00 for LianBio in the next year.
View the latest price targets for LIAN.

What is the current consensus analyst rating for LianBio?

LianBio currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for LIAN.

What other companies compete with LianBio?

Other companies that are similar to LianBio include Leap Therapeutics, Protara Therapeutics, Metagenomi, Maxpro Capital Acquisition and INmune Bio. Learn More about companies similar to LianBio.

How do I contact LianBio's investor relations team?

The company's listed phone number is 609-486-2308 and its investor relations email address is [email protected]. The official website for LianBio is www.lianbio.com. Learn More about contacing LianBio investor relations.